Stay updated with breaking news from Nasdaq Mxct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gagnon Securities LLC acquired a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 34,468 shares of the company’s stock, valued at approximately $188,000. Several other hedge funds have also recently bought and sold shares of […]
MaxCyte (NASDAQ:MXCT – Get Rating) and Science 37 (NASDAQ:SNCE – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership. Profitability This table compares MaxCyte and Science 37’s net margins, […]
MaxCyte (NASDAQ:MXCT – Get Rating) and Incyte (NASDAQ:INCY – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Analyst Ratings This is a summary of current ratings for MaxCyte and […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) CEO Douglas Doerfler sold 2,182 shares of the stock in a transaction on Tuesday, April 11th. The shares were sold at an average price of $5.00, for a total value of $10,910.00. Following the completion of the transaction, the chief executive officer now directly owns 333,197 shares in the […]
MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) EVP Thomas M. Ross sold 6,967 shares of the stock in a transaction dated Wednesday, April 5th. The stock was sold at an average price of $5.00, for a total transaction of $34,835.00. The transaction was disclosed in a legal filing with the SEC, which is available through this […]